SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (759)10/29/1998 5:31:00 PM
From: nigel bates  Read Replies (1) | Respond to of 3202
 
Rman,

As someone long INCY, that was the reply I was looking for.

Having said that, I wouldn't write off PKN. If they managed to divest their analytical instruments division, they could have up to $1bn more to play with. They have some good technology, and although Venter seems to have a talent for annoying others in the industry, he has a pretty interesting record. (Still, I sold my stock into the runup.)

nig



To: Rocketman who wrote (759)10/31/1998 2:59:00 AM
From: Vector1  Read Replies (3) | Respond to of 3202
 
Rman,
I have been told that PKN/ABI has a new sequencer that is awesome. However the first batch is going to Celera. Everyone else gets screwed. Talk about F-ing your customers.
V1


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News